International Journal of Clinical Oncology最新文献

{"title":"The Metazoan SpoT Homolog 1 promotes ferroptosis by regulating the intracellular redox cycle and iron levels in hepatocellular carcinoma.","authors":"Yuki Nakayama, Shinji Itoh, Takeo Toshima, Kyohei Yugawa, Shohei Yoshiya, Norifumi Iseda, Yuriko Tsutsui, Katsuya Toshida, Takuma Ishikawa, Tomoharu Yoshizumi","doi":"10.1007/s10147-025-02818-x","DOIUrl":"10.1007/s10147-025-02818-x","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis, a form of programmed cell death, is a potential target for cancer therapy. Metazoan SpoT Homolog 1 (MESH1) possesses intracellular NADPH phosphatase activity, which has been linked to ferroptosis. However, the molecular effects on the ferroptosis in hepatocellular carcinoma (HCC) remain unclear. This study aimed to investigate the relationship between MESH1 expression and the prognosis of patients with HCC, as well as its impact on ferroptosis in HCC cells.</p><p><strong>Methods: </strong>We used resected specimens from patients to assess the relationship between MESH1 expression and prognosis. HCC cell lines were used to evaluate the impact of MESH1 expression on the cell phenotype and ferroptosis through various assays, RNA sequencing, and an animal experiment with xenograft mice model.</p><p><strong>Results: </strong>We found that high MESH1 expression correlated with good outcomes. Further investigation demonstrated that MESH1 also exhibits NADPH phosphatase activity in HCC, contributing to increased sensitivity to ferroptosis when the ferroptosis inducer was used. Similar results were observed with other ferroptosis inducers, sorafenib and lenvatinib. Notably, RNA sequencing analysis of cells with MESH1 KD revealed a correlation between intracellular iron homeostasis and MESH1 levels. These results suggested that MESH1 also can affect ferroptosis sensitivity through changing intracellular iron levels. Tumors derived from MESH1 KD cells in xenograft mice showed reduced sensitivity to sorafenib and lenvatinib, further supporting the role of MESH1 ferroptosis regulation.</p><p><strong>Conclusion: </strong>This study suggests that MESH1 influences intracellular redox and iron regulatory pathways, both of which are linked to cellular processes associated with ferroptosis.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1818-1831"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment strategies and prognosis of superficial laryngo-pharyngeal cancer: a literature review.","authors":"Kazuchika Ohno, Takahiro Asakage","doi":"10.1007/s10147-025-02781-7","DOIUrl":"10.1007/s10147-025-02781-7","url":null,"abstract":"<p><p>Superficial laryngo-pharyngeal cancer (SLPC) is defined as that stage of the cancer in which \"cancer cells are confined to the subepithelial layer, without invasion of the muscularis propria, with or without lymph node metastasis.\" With the advances in endoscopic technologies and observation methods, numerous cases of SLPC have been reported in recent years. Less invasive oral resection methods, enabling organ preservation, have also been developed for the treatment of SLPC. However, it should be noted that the diagnosis of SLPC is based on the tumor thickness, which cannot be addressed by the TNM classification. Furthermore, although SLPC is generally associated with a good prognosis, a certain proportion of patients develop lymph node metastasis and/or multiple metachronous cancers, both of which may be expected to have an adverse impact on the prognosis. In addition, sufficient evidence has not accumulated for optimal post-treatment surveillance and factors affecting the risk of lymph node metastasis, and further investigation is required. In this review, we describe the epidemiology, general characteristics, diagnosis, treatment, and prognosis of SLPC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1681-1691"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Different outcomes by sex in metastatic gastrointestinal stromal tumor patients receiving imatinib: a trial-level analysis.","authors":"Antonella Venturino, Giuseppe Antonio Colloca","doi":"10.1007/s10147-025-02808-z","DOIUrl":"10.1007/s10147-025-02808-z","url":null,"abstract":"<p><strong>Background: </strong>Among gastrointestinal stromal tumors patients, many authors have reported longer overall survival for female sex regardless of stage. Other studies showed more favourable prognosis for young women, while others found no effect of sex on outcome. Few data about survival differences by sex are available on patients with unresectable/metastatic gastrointestinal stromal tumors (mGIST) receiving imatinib. The study aims to perform a trial-level analysis of metastatic gastrointestinal stromal tumors patients treated with imatinib to define the effect of sex on overall survival.</p><p><strong>Methods: </strong>After a systematic literature review, studies enrolling mGIST patients receiving upfront imatinib and reporting hazard ratios and confidence intervals of the relationship of sex with overall survival (OS) were selected. A meta-analysis was performed, calculating a global effect size. Finally, the study explored the effect on the relationship of other baseline variables, such as age, sex, tumor location, and patient origin.</p><p><strong>Results: </strong>Fifteen articles were selected, including 3612 patients. The meta-analysis documented longer OS among women, with significant overall effect size (HR 0.77, CI 0.71-0.84). Furthermore, there was no significant heterogeneity among studies (Q=9.13, p-value=0.8229; I²=0%), while the effect of the relationship was not confirmed for tumors originating in the stomach.</p><p><strong>Conclusions: </strong>The analysis documented better prognosis for female sex after upfront imatinib. The absence of heterogeneity between studies suggests that sex may condition a different response to imatinib. However, other factors, such as second malignancies and mutation patterns, may also contribute to the observed differences.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1797-1804"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis.","authors":"Laura Vertechy, Raffaella Ergasti, Cristina Chiamenti, Davide Arrigo, Ilary Ruscito, Alessandra Rizzi, Serena Maria Boccia, Carolina Maria Sassu, Giovanni Scambia, Anna Fagotti, Claudia Marchetti","doi":"10.1007/s10147-025-02817-y","DOIUrl":"10.1007/s10147-025-02817-y","url":null,"abstract":"<p><strong>Background: </strong>Prognosis for patients with early platinum-resistant Epithelial Ovarian Cancer (EOC) relapse after first-line chemotherapy remains poor. This study explores whether platinum rechallenge may be an option in this setting.</p><p><strong>Methods: </strong>In this retrospective, single-institute, observational study, we enrolled BRCA1/2 wild-type (BRCAwt) patients who underwent surgery (January 2017-July 2021) and relapsed within 6 months after first-line platinum-based chemotherapy. Platinum (P) rechallenge was compared with pegylated liposomal doxorubicin (PLD) or non-platinum/non-PLD therapy (weekly paclitaxel/gemcitabine/topotecan, PGT). To minimize selection bias, propensity score matching (PSM) analysis was performed.</p><p><strong>Results: </strong>Overall, 87 patients were identified: 18 (20.7%, P cohort), 50 (57.5%, PLD cohort) and 19 (21.8%, PGT cohort); after PSM, 54/87 patients were identified with similar characteristics, 18 for each group. Grade 3/4 toxicity events were more frequent in P group patients (13/18, 72.2%), compared to PDL (5/18, 27.8%) and PGT (7/18, 38.9%)(PvsPDL: p = 0.008; PvsPGT: p = 0.044; PDLvsPGT: p = 0.479; PvsPDLvsPGT: p = 0.021). Median progression-free survival (mPFS) was 9 months (P cohort) (CI 95%; 4.842-13.158), achieving a 4-month and 3-month increase compared to PLD (mPFS 5 months, p < 0.002) and PGT group (mPFS 6 months, p < 0.05), respectively. Median overall survival (mOS) benefit was preserved: 32 months (P cohort) compared to PLD (13 months, p = 0.001) and PGT (18 months, p = 0.01) groups. On multivariate analysis, platinum rechallenge was an independent prognostic factor for PFS (HR: 0.416; 95% CI: 0.215-0.807; p = 0.009) and OS (HR: 0.175; 95% CI: 0.061-0.503; p = 0.001). Results were consistent with the whole population.</p><p><strong>Conclusions: </strong>Platinum rechallenge showed promising survival outcomes for BRCAwt patients recurring within 6 months after first-line platinum-based chemotherapy.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1873-1881"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of cases with complete hydatidiform mole coexisting with a fetus: a single-center study.","authors":"Kaoru Niimi, Mayu Shibata, Kosuke Yoshida, Eiko Yamamoto, Seiji Sumigama, Yuko Yasui, Yuki Nishiko, Kimihiro Nishino, Hiroaki Kajiyama","doi":"10.1007/s10147-025-02815-0","DOIUrl":"10.1007/s10147-025-02815-0","url":null,"abstract":"<p><strong>Background: </strong>Complete hydatidiform moles coexisting with a fetus (CHMCF) are uncommon. Although CHMCF is associated with perinatal complications and post-molar gestational trophoblastic neoplasia (GTN), necessitating post-delivery chemotherapy, live birth remains feasible. This report presents 14 cases of CHMCF in Japan.</p><p><strong>Methods: </strong> We reviewed medical records of patients with CHMCF treated at our hospital from 2000 to 2020 and summarized clinical data, including maternal age, pregnancy details, delivery outcomes, fertility treatments, serum human chorionic gonadotropin (hCG) levels, and ultrasonography findings.</p><p><strong>Results: </strong>Fourteen cases of CHMCF were diagnosed. The average age of the mothers was 30.6 years, with the majority conceiving following fertility treatment. The mean gestational age at diagnosis was 12 weeks. Six patients maintained their pregnancies, leading to two live births through emergency cesarean section. Eight patients exhibited spontaneous regression following treatment and pregnancy interruption, achieving negative serum hCG levels within 17.4 weeks. Six patients experienced post-molar GTN, including the two who had live births. One patient presented with FIGO stage I disease, while five patients had stage III lung metastases. All patients received chemotherapy, averaging nine courses, achieving remission within 13.7 weeks.</p><p><strong>Conclusion: </strong> The occurrence of GTN was higher after CHMCF than after typical complete hydatidiform moles. Despite the heightened risk of premature birth, some patients with CHMCF who maintain their pregnancies can successfully deliver live babies. Informed consent is essential for patients with CHMCF when considering pregnancy continuation. A team approach involving gynecological oncologists, obstetricians, and neonatologists is essential for effective diagnosis and treatment.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1866-1872"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of a novel perioperative quality assessment metric, trifecta, for radical cystectomy.","authors":"Mahito Atsuta, Fumihiko Urabe, Kosuke Iwatani, Masataka Kubo, Naoki Uchida, Hirokazu Kagawa, Naoya Tomomasa, Shun Saito, Takayuki Sano, Wataru Fukuokaya, Kazuhiro Takahashi, Takafumi Yanagisawa, Shunsuke Tsuzuki, Takahiro Kimura, Jun Miki","doi":"10.1007/s10147-025-02791-5","DOIUrl":"10.1007/s10147-025-02791-5","url":null,"abstract":"<p><strong>Background: </strong>Assessing the quality of surgical procedures is crucial for improving outcomes in radical cystectomy (RC). While the Pentafecta metric has been used, its reliance on the absence of local recurrence within 1 year delays postoperative assessment. For timely clinical decision-making, a new metric that facilitates earlier evaluation is needed. We propose such a metric, named \"Trifecta\". We evaluated its impact on prognosis and identified predictors for achieving it.</p><p><strong>Methods: </strong>The \"Trifecta\" metric was defined as meeting three criteria: adequate lymphadenectomy (≥ 10 nodes), negative surgical margins, and absence of Clavien-Dindo grade 3-5 complications within 30 days after surgery. This retrospective study analyzed data from patients who underwent RC and lymphadenectomy between April 2014 and June 2024. Kaplan-Meier analysis and Cox proportional hazards models were used to assess oncological outcomes, while logistic regression was used to identify predictors for failing to achieve \"Trifecta\" .</p><p><strong>Results: </strong>Of the 196 patients included, 121 (61.7%) achieved \"Trifecta\" and this was significantly associated with improved intrapelvic RFS (HR 0.42; P = 0.014), CSS (HR 0.56; P = 0.032), and OS (HR 0.57; P = 0.020) but not MFS (HR 0.85; P = 0.620). Low serum levels of albumin were significantly associated with \"Trifecta\" failure (OR 2.06; P = 0.021), but not with survival outcomes.</p><p><strong>Conclusion: </strong>Achieving \"Trifecta\" was associated with improved survival outcomes, and low serum levels of albumin predicted a higher likelihood of failure to achieve it. The \"Trifecta\" metric enables early and clinically relevant evaluation of surgical quality, offering a practical alternative to traditional metrics.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1832-1840"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative neurological safety of novel hormonal therapies in advanced prostate cancer: a Bayesian network meta-analysis of randomized trials.","authors":"Ganesh Bushi, Aftab Ullah, Urooj Khan, Haiqa Sayyed, Muhammed Shabil","doi":"10.1007/s10147-025-02869-0","DOIUrl":"https://doi.org/10.1007/s10147-025-02869-0","url":null,"abstract":"<p><strong>Background: </strong>Novel hormonal agents (NHAs), including enzalutamide, abiraterone acetate, apalutamide, and darolutamide, have improved survival in advanced prostate cancer (PCa). However, their potential neurological adverse effects (AEs)-notably cognitive impairment, seizures, and falls-raise safety concerns, particularly in older adults. This study aimed to compare the neurological safety profiles of NHAs in men with advanced PCa using a Bayesian network meta-analysis (NMA).</p><p><strong>Methods: </strong>We conducted a systematic review and Bayesian NMA following PRISMA-NMA guidelines. Comprehensive searches of PubMed, EMBASE, and Web of Science were completed through May 21, 2025. Eligible randomized controlled trials (RCTs) compared NHAs plus androgen deprivation therapy (ADT) with placebo, ADT, or other NHAs. Neurological AEs of interest included cognitive impairment, falls, and seizures. Bayesian random-effects models were used to calculate risk ratios (RRs) with 95% credible intervals (CrIs). Treatments were ranked using surface under the cumulative ranking curve (SUCRA) values.</p><p><strong>Results: </strong>Twenty-five RCTs with over 19,000 patients were included. No treatments showed a statistically significant increased risk of neurological AEs. Enzalutamide had the highest estimated risk for cognitive impairment (RR 3.88; 95% CrI, 0.697-22.1) and seizures (RR 13.8; 95% CrI, 0.983-1.07 × 10³), although not statistically significant. Darolutamide and nonsteroidal antiandrogens exhibited the most favorable neurological safety profiles across outcomes based on SUCRA rankings.</p><p><strong>Conclusion: </strong>Although no NHA significantly increased neurological AEs, enzalutamide showed the highest estimated risk, while darolutamide and NSAAs ranked best for neurological safety. Darolutamide may be preferred in elderly patients, highlighting the need for further long-term safety data.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of antibiotic use on survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor and chemotherapy.","authors":"Nobuaki Ochi, Eiki Ichihara, Toshihide Yokoyama, Koji Inoue, Tomoki Tamura, Hiromi Watanabe, Ichiro Takata, Hirohisa Kano, Kayo Nakamura, Haruyuki Kawai, Masaaki Inoue, Nobukazu Fujimoto, Hirohisa Ichikawa, Chihiro Ando, Isao Oze, Nagio Takigawa, Yoshinobu Maeda, Katsuyuki Hotta","doi":"10.1007/s10147-025-02860-9","DOIUrl":"https://doi.org/10.1007/s10147-025-02860-9","url":null,"abstract":"<p><strong>Background: </strong>Evidence suggests that antibiotic (ATB) use may negatively impact the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC). We previously demonstrated that ATB use was significantly associated with decreased survival in NSCLC patients receiving ICI monotherapy. This study aimed to investigate the effect of ATB use on survival in NSCLC patients undergoing combined ICI and chemotherapy.</p><p><strong>Patients and methods: </strong>We evaluated the impact of ATB on survival in NSCLC patients treated with ICIs and chemotherapy in this multicenter retrospective study. We analyzed outcomes such as progression-free survival (PFS) and overall survival (OS) in patients who received ATB within 2 months before or 1 month after starting ICI and chemotherapy combination therapy.</p><p><strong>Results: </strong>Among 451 patients, 113 received ATB (ATB group) and 338 did not (ATB-unexposed). The median PFS was 7.1 months in the ATB group and 8.4 months in the ATB-unexposed group. The median OS was 18.0 months in the ATB group compared to 23.8 months in the ATB-unexposed group, indicating a significant reduction in both PFS and OS for the ATB group. Notably, this negative impact was not observed in patients who used probiotics (PFS: 6.0 vs. 7.6 months, p = 0.355; OS: 16.7 months vs. not reached (NR), p = 0.179).</p><p><strong>Conclusion: </strong>ATB use was significantly associated with poorer survival outcomes in NSCLC patients treated with combined ICI and chemotherapy, but this effect was attenuated by probiotics.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative chemotherapy after conversion surgery for clinical stage IV gastric cancer: a propensity score-matched analysis.","authors":"Yasunori Masuike, Takeshi Omori, Kazuyoshi Yamamoto, Yoshitomo Yanagimoto, Yuki Ushimaru, Kei Yamamoto, Takashi Kanemura, Takahito Sugase, Norihiro Matsuura, Ryota Mori, Masatoshi Kitakaze, Masahiko Kubo, Yasunari Fukuda, Hisateru Komatsu, Masaaki Miyo, Toshinori Sueda, Yoshinori Kagawa, Kunihito Goto, Shogo Kobayashi, Masayuki Ohue, Hiroshi Miyata","doi":"10.1007/s10147-025-02867-2","DOIUrl":"https://doi.org/10.1007/s10147-025-02867-2","url":null,"abstract":"<p><strong>Background: </strong>Conversion surgery following systemic chemotherapy has emerged as a promising strategy for clinical stage IV gastric cancer. However, the role of postoperative chemotherapy in improving survival outcomes remains unclear. This study aimed to evaluate the impact of postoperative chemotherapy on survival, comparing single-agent and combination regimens.</p><p><strong>Methods: </strong>We conducted a single-institution retrospective study of patients who underwent gastrectomy after induction chemotherapy for clinical stage IV gastric cancer between 2007 and 2021. Patients receiving postoperative chemotherapy were categorized into single-agent and combination therapy groups. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves and Cox proportional hazard models. Propensity score matching was applied to minimize selection bias.</p><p><strong>Results: </strong>Among 128 eligible patients, 45 (35.2%) received single-agent chemotherapy, while 83 (64.8%) received combination therapy. After propensity score matching, 70 patients (35 in each group) were analyzed. The median OS was 29 months, and the median PFS was 14 months, with no significant differences between single-agent and combination chemotherapy groups (OS: p = 0.841; PFS: p = 0.831). Residual tumor was a strong predictor of poor survival (p = 0.010). Subgroup analysis suggested a potential PFS benefit of combination therapy in ypStage IV patients without residual tumor (p = 0.04).</p><p><strong>Conclusion: </strong>Postoperative combination chemotherapy did not significantly improve survival outcomes compared with single-agent regimen in the overall cohort. However, specific subgroups, particularly ypStage IV patients without residual tumor, may benefit from intensified therapy.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancer.","authors":"Taiju Ando, Yuko Oya, Yumi Tomiie, Kimio Ogawa, Tomoki Kuki, Yosuke Tanabe, Hisayuki Kato, Kazuyoshi Imaizumi, Yatsuka Hibi, Kenji Kawada","doi":"10.1007/s10147-025-02861-8","DOIUrl":"https://doi.org/10.1007/s10147-025-02861-8","url":null,"abstract":"<p><strong>Background: </strong>BRAF V600E mutation is a key oncogenic driver commonly found in papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC). Dabrafenib plus trametinib combination therapy targeting this mutation has shown promising activity in clinical trials. This study aimed to verify the real-world effectiveness of this combination therapy in patients with BRAF V600E-positive PTC and ATC.</p><p><strong>Methods: </strong>We retrospectively investigated adult patients with BRAF V600E-positive PTC and ATC who were treated with dabrafenib plus trametinib at a single university hospital in Japan.</p><p><strong>Results: </strong>Between January 2024 and December 2024, 10 patients with PTC and 6 patients with ATC were identified, among whom 13 patients (81%) had been previously treated with lenvatinib. An objective response was observed in 5 patients with PTC (50%) and 4 patients with ATC (67%). The median progression-free survival and overall survival were not reached in patients with PTC, and were 2.7 months and 3.6 months, respectively, in patients with ATC. Partial regression of intracranial metastatic tumors was observed in 1 of the 2 patients with brain metastases at baseline. Rechallenge with another BRAF/MEK inhibitor combination therapy, encorafenib plus binimetinib, was attempted in 2 patients with ATC and demonstrated clinically meaningful responses.</p><p><strong>Conclusions: </strong>Dabrafenib plus trametinib combination therapy demonstrated clinical effectiveness in patients with BRAF V600E-positive thyroid cancer, with response rates comparable to those observed in clinical trials. However, tumor shrinkage did not appear to translate into improved survival in patients with ATC, highlighting the limitations of current targeted therapies in managing this aggressive subtype.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}